PDCD1 and Merkel cell skin cancer: For MCC-diagnosed patients, there are currently three approved antibodies by the Food and Drug Administration (FDA): avelumab as anti-programmed death-ligand 1 (anti-PD-L1) and pembrolizumab and retifanlimab as anti-PD-1 monoclonal antibody treatments.